Comorbid pathology of the cardiovascular system in patients suffering from morphea
https://doi.org/10.51523/2708-6011.2020-17-2-8
Abstract
Objective: to assess the parameters of echocardiography, structure of cardiovascular pathology in patients suffering from morphea. Material and methods. The echocardiographic data and cardiovascular pathology were studied in 74 patients with morphea. Results. Diastolic dysfunction of the left ventricle was revealed in 37.5 % of the morphea patients, dilatation of the left atrium was found in 10.8% of the patients, pathological regurgitation on the aortic valve - in 21.62 %. 86.5 % of the patients had morphea combined with arterial hypertension. Conclusion: Such comorbid pathologies as arterial hypertension, dilatation of the left atrium, pathological regurgitation on the aortic valve and left ventricular diastolic dysfunction are common for patients with morphea.
About the Authors
L. A. Poroshina
Gomel State Medical University
Belarus
Belarus
Larisa A. Poroshina – Senior lecturer at Department of Internal Diseases No.2 with the course of the Faculty of Professional Development and Retraining of the EI «Gomel State Medical University»
e-mail: plary@mail.ru
A. M. Yurkovskiy
Gomel State Medical University
Belarus
Belarus
Alexei М. Yurkovskiy – Candidate of Medical Sciences, Associate Professor at Department of Internal Diseases No.3 with the courses of Radiodiagnostics, Radiotherapy and the Faculty of Professional Development and Retraining of the EI «Gomel State Medical University»
N. F. Bakalets
Republican Research Center for Radiation Medicine and Human Ecology
Belarus
Belarus
Natalya F. Bakalets – Candidate of Medical Sciences, Associate Professor, therapist of the Therapeutic Department for liquidators and the Chernobyl-affected population of the SI «Republican Research Center for Radiation Medicine and Human Ecology»
References
1. Careta MF, Romiti R. Localized scleroderma: clini-cal spectrum and therapeutic update. An Bras Dermatol. 2015;90(1):62-73. DOI: 10.1590/abd 1806-4841.20152890
2. Shelley E. Additional Symptoms Associated with Morphea. [Электронный ресурс]. International Scleroderma Network (ISN) 2002 [дата обраще-ния: 2019 Апрель 12]. https://sclero.org/scleroderma/ types/localized/morphea/associated.html/
3. Bali G, Szilvási A, Inotai D, Varga A, Sárdy M, Kárpáti S, Medvecz M, Szegedi A, Hidvégi B. Ko-morbidität von lokalisierter Sklerodermie und primär biliärer Cholangitis. J Dtsch Dermatol Ges. 2018;16(11):1323-28. DOI: 10.1111/ddg.13693
4. Gümüşsu K, Rezvani A, Özlem SU, Özaras N, Güler M. Case Report: Coexistence of ankylosing spondylitis with morphea. Archives of Rheumatol-ogy. 2014; 29: 143-46. DOI:10.5606/archrheumatol. 2014.3919
5. Wielosz E, Kurowska M, Suszek D, Majdan M. Coexistence of diabetes mellitus type 1 with difuse systemic sclerosis – case report and litera-ture review. Reumatologia. 2017; 55(2): 104-7. DOI: 10.5114/reum.2017.67607.
6. Serpil T, Sevil A, Hande EÖZ, Nilüfer VB. The Comorbidity of Morphea, Raynaud's Phenomenon and Sarcoidosis: Case Repor. Turkiye Klinikleri Dermatoloji. 2014;24(3):106-109. DOI: 10.5336/dermato.2014-40406
7. Dańczak-Pazdrowska A, Polańska A, Synakiewicz J, Gurgu E, Molińska-Glura M, Ruchała M, Żaba R, Adamsk Z. Morphea and antithyroid antibodies. Postepy Dermatol Alergol. 2018;35(5): 470-73. DOI: 10.5114/ada.2018.75839
8. Peralta-Amaro AL, Cruz-Domínguez MP, Olvera-Acevedo A, Vera-Lastra OL Prevalence of meta-bolic syndrome and insulin resistance in system sclerosis. Rev Med Inst Mex Seguro Soc. 2015;3(4):476-83.
9. Mok MY, Lau CS, Hin Chiu SS, Kwan Tso AW, Lo Y, Chun Law LS, Mak KF, Wong WS, Khong PL, Ling Lam KS. Systemic Sclerosis is an Independ-ent Risk Factor of Increased Coronary Artery Cal-cium Deposition. [Электронный ресурс]. Arthritis & Rheumatism; Published Online: April 28, 2011. [дата обращения: 2019 Апрель 12]. http://onlinelibrary. wiley.com. DOI/10.1002/art.30283/abstract
10. Oreska S, Tomcik M. Atherosclerosis and Cardio-vascular Risk in Systemic Sclerosis. [Электронный ресурс]. Open access peer-reviewed chapter. 2016. [дата обращения: 2019 Апрель 15]. https://www. intechopen.com/books/systemic-sclerosis/ ath-erosclerosis-and-cardiovascular-risk-in-systemic-sclerosis
11. Панкратов ОВ, Порошина ЛА. Ограниченная склеродермия: этиопатогенез, клиническая картина, диагностика, лечение. Здравоохране-ние. 2019;6:28-38.
12. Кочуева МН, Павлова ГБ, Павлов СБ. Взаимо-связь показателей диастолической функции левого желудочка сердца и концентраций ци-токинов в сыворотке крови у больных систем-ной склеродермией. Вісник Сумського Держав-ного Університету. Серія Медицина. 2005;3(75):190-3.
13. Козлова ЛК, Тамгина ТФ, Нуждина ТВ, Анто-ненко ТВ, Алехина ЕМ. Функциональная оценка состояния сердца по данным эхокардиографии и состояния липидного обмена у больных си-стемной склеродермией и системной красной волчанкой. Терапевтический Архив. 2001;73(5):33-6.
14. Vemulapalli S, Cohen L, Hsu V. Prevalence and risk factors for left ventricular diastolic dysfunc-tion in a scleroderma cohort. Scand J Rheumatol. 2017;46(4):281-287. DOI: 10.1080/03009742. 2016.1206963
15. Вилкенсхоф У, Крук И. Справочник по эхокар-диографии: пер с немецкого. Москва, РФ: Мед. лит; 2009. 240 с.
Review
For citations:
Poroshina L.A., Yurkovskiy A.M., Bakalets N.F. Comorbid pathology of the cardiovascular system in patients suffering from morphea. Health and Ecology Issues. 2020;(2):57-63. (In Russ.) https://doi.org/10.51523/2708-6011.2020-17-2-8
Views: 360
Email this article 